Sugi Predict

Sugi Predict / Compounds / SCHEMBL8909664

SCHEMBL8909664

SCHEMBL8909664

CC(C)(C)C(=O)[C@@H](c1ccccc1)N1CCC(O)CC1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ KCNA3 P22001 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ OPRM1 P35372 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8909675 0.86 KCNH2 (0.49) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL8906984 0.84 LMNA (0.65) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL15429939 0.84 LMNA (0.65) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL8907109 0.83 GAA (0.66) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL890183 0.83 LMNA (0.50) LMNACYP3A4GAAMEN1KMT2A
SCHEMBL12174966 0.83 LMNA (0.50) LMNACYP3A4GAAMEN1KMT2A
SCHEMBL11407476 0.83 LMNA (0.50) LMNACYP3A4GAAMEN1KMT2A
SCHEMBL8906944 0.83 DPP4 (0.44) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL8906962 0.83 DPP4 (0.44) LMNACYP3A4HIF1AGAAMEN1
SCHEMBL755184 0.83 LMNA (0.67) LMNACYP3A4GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
US-8673954-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-03-18 — — US disclosed
US-8637561-B2 Linked diimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-01-28 — — US disclosed
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS ENANTA PHARMACEUTICALS, INC (US) 2013-11-07 — — US disclosed
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-09 — — US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 LMNA 3064/4885CYP3A4 56/4885HIF1A 2120/4885
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 LMNA 2096/4885CYP3A4 136/4885HIF1A 1632/4885
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 LMNA 2724/4885CYP3A4 138/4885HIF1A 2248/4885
US-20130295049-A1 LINKED DIBENZIMIDAZOLE ANTIVIRALS EIF2AK2, ZC3HAV1, NSUN2 LMNA 3035/4885CYP3A4 87/4885HIF1A 2174/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L LMNA 2786/4885CYP3A4 40/4885HIF1A 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.